Trial · NCT02870920

Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer

NCT02870920, Phase 2, Completed, Canadian Cancer Trials Group; results first posted 2021-01-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer. Trials, record NCT02870920. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02870920

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
NCT number: NCT02870920
Status: Completed
Phases: Phase 2
Enrollment: 180 participants, actual
Lead sponsor: Canadian Cancer Trials Group
Conditions: Colorectal Cancer
Interventions: Tremelimumab, Durvalumab, Best Supportive Care
First posted: 2016-08-17
Last updated: 2023-12-08
Results first posted: 2021-01-19

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Survival	24 months	Time from randomization to death from any cause with patients who were alive at the time of the final analysis or who became lost to follow-up censored at their last date known to be alive.
Secondary	Progression-free Survival	24 months	Defined as the time from randomization to the first objective documentation of disease progression, defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, or death due to any cause with patients who had not progressed or died at the time of final analysis censored on the date of the last tumour assessment.
Secondary	Objective Response Rate	24 months	Defined as percentage of participants with objective response over all participants randomized. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Survival	24 months	All randomized patients.	months	MEDIAN
SECONDARY	Progression-free Survival	24 months	All randomized patients	Months	MEDIAN
SECONDARY	Objective Response Rate	24 months	All randomized patients	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Overall Survival	Best Supportive Care		4.1	90% Confidence Interval 3.3 to 6.0	months
Overall Survival	Durvalumab Plus Tremelimumab and Best Supportive Care		6.6	90% Confidence Interval 6.0 to 7.4	months
Progression-free Survival	Best Supportive Care		1.9	90% Confidence Interval 1.8 to 1.9	Months
Progression-free Survival	Durvalumab Plus Tremelimumab and Best Supportive Care		1.8	90% Confidence Interval 1.8 to 1.9	Months
Objective Response Rate	Best Supportive Care	Responded	0		Participants
Objective Response Rate	Durvalumab Plus Tremelimumab and Best Supportive Care	Responded	1		Participants
Objective Response Rate	Best Supportive Care	Not responded	61		Participants
Objective Response Rate	Durvalumab Plus Tremelimumab and Best Supportive Care	Not responded	118		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Best Supportive Care	61
Overall Study	STARTED	Durvalumab Plus Tremelimumab and Best Supportive Care	119
Overall Study	COMPLETED	Best Supportive Care	61
Overall Study	COMPLETED	Durvalumab Plus Tremelimumab and Best Supportive Care	119
Overall Study	NOT COMPLETED	Best Supportive Care	0
Overall Study	NOT COMPLETED	Durvalumab Plus Tremelimumab and Best Supportive Care	0

Source ClinicalTrials.gov

Adverse events208

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Hypothyroidism	Endocrine disorders	Best Supportive Care	1	61
other	Hypothyroidism	Endocrine disorders	Durvalumab Plus Tremelimumab and Best Supportive Care	10	118
other	Abdominal distension	Gastrointestinal disorders	Best Supportive Care	2	61
other	Abdominal distension	Gastrointestinal disorders	Durvalumab Plus Tremelimumab and Best Supportive Care	6	118
other	Abdominal pain	Gastrointestinal disorders	Best Supportive Care	18	61
other	Abdominal pain	Gastrointestinal disorders	Durvalumab Plus Tremelimumab and Best Supportive Care	53	118
other	Constipation	Gastrointestinal disorders	Best Supportive Care	14	61
other	Constipation	Gastrointestinal disorders	Durvalumab Plus Tremelimumab and Best Supportive Care	49	118
other	Diarrhea	Gastrointestinal disorders	Best Supportive Care	6	61
other	Diarrhea	Gastrointestinal disorders	Durvalumab Plus Tremelimumab and Best Supportive Care	37	118

1 to 10 of 208Source ClinicalTrials.gov

See all 208 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Best Supportive Care	54	61
Total, all-cause mortality	Durvalumab Plus Tremelimumab and Best Supportive Care	100	118
Total, other adverse events	Best Supportive Care	51	61
Total, other adverse events	Durvalumab Plus Tremelimumab and Best Supportive Care	116	118
Total, serious adverse events	Best Supportive Care	0	61
Total, serious adverse events	Durvalumab Plus Tremelimumab and Best Supportive Care	55	118

Source ClinicalTrials.gov

Papers4

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
32379280	RESULT	PubMed
36007218	DERIVED	PubMed
39178370	DERIVED	PubMed
39631846	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Best Supportive Care vs Durvalumab Plus Tremelimumab and Best Supportive Care: deaths from any cause	Trial comparisons
Best Supportive Care vs Durvalumab Plus Tremelimumab and Best Supportive Care: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02870920

GET https://conductscience.org/api/trials/v1/NCT02870920/events?page=2

API reference For AI assistants